Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/6/2009 First Published: 4/23/2004


1.		Phase III Randomized Study of Exemestane in Postmenopausal Women at Increased Risk of Developing Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				35 and over				Other, Pharmaceutical / Industry				CAN-NCIC-MAP3 PFIZER-EXEAPO-0028-150, ExCel, NCT00083174, MAP3

Last Modified: 7/23/2008 First Published: 8/3/2007


2.		Phase III Randomized Study of the Effects of Dietary Soy on Estrogens in Breast Fluid, Serum, and Urine Samples From Healthy Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Active				30 to 45				NCI				UHM-CHS-4116 CHS 14116, NCT00513916

First Published: 10/31/2007


3.		Phase III Randomized Study of Continuous Letrozole Versus Intermittent Letrozole in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive, Early-Stage Breast Cancer After Completion of 4 to 6 Years of Prior Adjuvant Endocrine Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				Postmenopausal				Other				IBCSG-35-07 IBCSG-35-07, BIG-1-07-SOLE, EUDRACT-2007-001370-88, NCT00553410

Last Modified: 8/27/2008 First Published: 5/5/2008


4.		Phase III Randomized Study of Letrozole in Preventing Breast Cancer in Postmenopausal Women With the BRCA1/BRCA2 Mutation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Active				40 to 69				Other, Pharmaceutical / Industry				FNCLCC-ONCO-03/0701 FNCLCC-ONCO 03/0701 - LIBER, EU-20806, NOVARTIS-FNCLCC-ONCO 03/0701, NCT00673335

First Published: 3/18/2008


5.		Randomized Study of Prophylactic Cranial Radiotherapy in Women With Metastatic or Locally Advanced Breast Cancer Previously Treated With Trastuzumab (Herceptin®) and Taxane Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention, Treatment				Active				18 and over				Other				ACCOG-HER-PCI ACCOG-HER-PCI, ISRCTN64624715, EU-20822, NCT00639366


6.		Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				30 to 75				Other				GD-10-08 NCT00808522

Last Modified: 8/27/2008 First Published: 3/24/2004


7.		Phase II Pilot Chemoprevention Study of Deslorelin in Combination With Low-Dose Add-Back Estradiol and Testosterone in Premenopausal Women With or Without a BRCA Gene Mutation Who Are at High Risk for Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				21 to 48				NCI				CHNMC-IRB-02164 NCT00080756

Last Modified: 1/5/2009 First Published: 5/28/2004


8.		Phase II Study of Exemestane in Postmenopausal Women at High Risk for Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				Postmenopausal				NCI				GUMC-2007-313 NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313

Last Modified: 10/11/2007 First Published: 8/24/2004


9.		Phase II Randomized Pilot Study of Letrozole in Postmenopausal Women at Increased Risk For Breast Cancer Based on Elevated Estradiol Levels

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				35 and over				NCI				DFCI-00024 UCLA-0210012-02, NCT00090857


10.		Soy Protein and Breast Cancer Risk Reduction

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				30 to 40				Other				02-422 Army's HSRRB log no. A-10926, UTMB GCRC 533, DAMD17-01-1-0417, NIH NCRR GCRC M01 RR00073, NCT00204477

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute